 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Federal Circuit Judges Considered USPTO Policy, Industry Impact in Ruling on Myriad's Gene Patents
August 22, 2012
Federal Circuit Judges Considered USPTO Policy, Industry Impact in Ruling on Myriad's Gene Patents
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not
August 3, 2011 / Pharmacogenomics Reporter - At Appeals Hearing, Myriad Outlines Stance on BRCA IP Rights for Whole-Genome Sequencing
April 6, 2011 / Pharmacogenomics Reporter - Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter - At Federal Circuit Hearing, Plaintiffs in Myriad Case Fight to Keep Gene Patentability Issue on the Table
July 25, 2012 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter